Cytokinetics Announces NMPA Approval of MYQORZO® (aficamten) in China for Patients with Obstructive Hypertrophic Cardiomyopathy – Cytokinetics

Written by

admin

in

  1. Cytokinetics Announces NMPA Approval of MYQORZO® (aficamten) in China for Patients with Obstructive Hypertrophic Cardiomyopathy  Cytokinetics
  2. Targeted Therapy Nears EU Approval for Obstructive HCM  Medscape
  3. Cytokinetics Receives Positive CHMP Opinion for MYQORZO® (aficamten) in the Treatment of Obstructive Hypertrophic Cardiomyopathy, Final Decision Expected Q1 2026  Quiver Quantitative
  4. Cytokinetics Wins China Approval For Myqorzo In Obstructive Hypertrophic Cardiomyopathy  Nasdaq
  5. Cytokinetics Announces NMPA Approval of MYQORZO®  GlobeNewswire

Continue Reading

More posts